3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Cisplatin
6
Paclitaxel
4
pembrolizumab
3
Fluorouracil
3
Carboplatin
3
tislelizumab
2
Taxes
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Injections
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
lenvatinib
1
durvalumab
1
cixutumumab
1
apatinib
1
Tegafur
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiation
1
Levoleucovorin
1
Laparoscopy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Fulvestrant
1
Docetaxel
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Histamine H2 Antagonists
×
30 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled